Saturna Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Saturna Capital’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-40,000	Closed	-$1.6M	–	368
2013 Q4	$1.6M	Sell	40,000 -10,000	-20%	-$394K	0.04%	132
2013 Q3	$1.89M	Sell	50,000 -589	-1%	-$23K	0.05%	139
2013 Q2	$1.98M	Buy	+50,589	New	+$1.97M	0.05%	137

Other funds holding TEVA

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

SFM

Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return

Saturna Capital's TEVA Position: Q1 2014 in Review

Saturna Capital sold out of Teva Pharmaceuticals (TEVA) in Q1 2014, closing a stake of 40,000 shares — an estimated $1.6M sold.

Saturna Capital first reported a position in TEVA in Q2 2013 and held it in 3 quarters. The position peaked at $1.98M in Q2 2013. 770 funds tracked by Wall St. Rank hold TEVA as of Q1 2014.

Saturna Capital reported no remaining Teva Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
Saturna Capital sold 40,000 Teva Pharmaceuticals shares in Q1 2014, an estimated $1.6M.
Saturna Capital first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 3 quarters.
Saturna Capital's Teva Pharmaceuticals position peaked at $1.98M in Q2 2013.
770 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2014.

Based on Saturna Capital's 13F filing for Q1 2014, filed 14 May 2014.